2026
Circulating microRNA signatures for diagnosis and prediction of curve progression in pediatric patients with idiopathic scoliosis
ORLÍČKOVÁ, Jana; Michael LUJC; Michal GALKO; Dagmar AL TUKMACHI; Ondřej SLABÝ et al.Základní údaje
Originální název
Circulating microRNA signatures for diagnosis and prediction of curve progression in pediatric patients with idiopathic scoliosis
Autoři
ORLÍČKOVÁ, Jana ORCID; Michael LUJC; Michal GALKO ORCID; Dagmar AL TUKMACHI; Ondřej SLABÝ a Martin REPKO
Vydání
JOURNAL OF ORTHOPAEDIC SURGERY AND RESEARCH, LONDON, BMC, 2026, 1749-799X
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30211 Orthopaedics
Stát vydavatele
Velká Británie a Severní Irsko
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 2.800 v roce 2024
Označené pro přenos do RIV
Ano
Organizační jednotka
Lékařská fakulta
UT WoS
EID Scopus
Klíčová slova anglicky
Idiopathic scoliosis; Progression risk; MicroRNA profiling; NGS; Biomarker study
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 8. 4. 2026 13:32, Mgr. Tereza Miškechová
Anotace
V originále
BackgroundIdiopathic scoliosis (IS) is the most common pediatric spinal deformity, yet no biomarker currently enables early diagnosis or reliable prediction of progression to guide individualized treatment. Circulating microRNAs (miRNAs) are promising non-invasive biomarkers reflecting multifactorial disease mechanisms. MethodsIn our prospective monocentric study, a Czech cohort comprising 114 pediatric IS patients at the time of diagnosis and 89 age-matched healthy controls was studied. Risk groups were defined based on the final Cobb angle at the end of follow-up at skeletal maturity. Plasma miRNA profiles were obtained by small RNA sequencing and analyzed for differential expression. Logistic regression models were used to construct miRNA diagnostic and prognostic signatures, validated by leave-one-out cross-validation (LOOCV). ResultsDifferential expression analysis identified 48 miRNAs with significantly different expression in the blood plasma of IS patients and controls (adj. p < 0.05), and plasma miR-4451 to have decreased levels in high-risk compared to low- and medium-risk IS patients (adj. p < 0.01). A 28-miRNA diagnostic signature distinguished IS patients from controls with AUC = 0.95 (sensitivity 88%, specificity 92%) and LOOCV accuracy = 0.85. For prognosis, comparison of high-risk versus low/medium-risk patients revealed a 7-miRNA prognostic signature, achieving AUC = 0.83, sensitivity 82%, specificity 74% and LOOCV accuracy = 0.81. Notably, the incorporation of clinical variables such as age or sex did not improve significantly model performance. ConclusionsOur study highlights the clinical utility of miRNA-based models for precise diagnosis and individualized patient management and supports further validation in larger, independent cohorts.
Návaznosti
| NU21-08-00521, projekt VaV |
|